At the end of the fiscal year, Immunogen Inc has the cash and cash equivalents of $262.3 million, compared with $267.1 million in the previous year. The company had no long term debt, compared with $2.05 million in the previous year. Immunogen Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $2.51, Immunogen Inc is traded at 73.7% discount to its historical median P/S valuation band of $9.54.
IMGN
News 
Market Data 
Discover 
